Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen

Catherine M. Dowling, Melissa Assel, John E. Musser, Joshua J. Meeks, Daniel D. Sjoberg, George Bosl, Robert Motzer, Dean Bajorin, Darren Feldman, Brett S. Carver, Joel Sheinfeld*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Objective: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Methods: We compared those patients with 100% EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND. Results: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Twenty-six percent of patients presented with metastatic disease outside the retroperitoneum. Patients with mixed histologies tended to have worse International Germ Cell Cancer Collaborative Group risk compared to those with EC at orchiectomy (P =.037). Histology at PC-RPLND revealed fibrosis or necrosis in 76%, mature teratoma in 19% and viable cancer in 4%. Over one-third of the patients had a residual mass of <1 cm prior to RPLND; of whom 15% harbored mature teratoma in PC-RPLND histology. The Kaplan–Meier estimated probability of recurrence at 5 years of follow-up was 3.1% (95% CI 1.2%, 8.0%) for EC histology, 7.3% lower than mixed histology. For cancer-specific mortality, the Kaplan–Meier estimated probability at 5 years was 4.6% (95% CI 3.3%, 6.3%) and 1.7% (95% CI 0.4%, 6.8%) for mixed and pure EC histologies, respectively. Conclusion: Approximately 20% of patients with pure EC had teratoma at PC-RPLND. We have shown that those with a maximum node size of <1 cm should not be precluded from RPLND.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalUrology
Volume114
DOIs
StatePublished - Apr 2018

Fingerprint

Embryonal Carcinoma
Orchiectomy
Lymph Node Excision
Histology
Drug Therapy
Teratoma
Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Cisplatin
Testis
Neoplasms
Fibrosis
Necrosis
Pathology
Recurrence
Mortality

ASJC Scopus subject areas

  • Urology

Cite this

Dowling, Catherine M. ; Assel, Melissa ; Musser, John E. ; Meeks, Joshua J. ; Sjoberg, Daniel D. ; Bosl, George ; Motzer, Robert ; Bajorin, Dean ; Feldman, Darren ; Carver, Brett S. ; Sheinfeld, Joel. / Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. In: Urology. 2018 ; Vol. 114. pp. 133-138.
@article{8712fd22b2b94a45b0d5e6c3471fc4cf,
title = "Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen",
abstract = "Objective: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Methods: We compared those patients with 100{\%} EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND. Results: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Twenty-six percent of patients presented with metastatic disease outside the retroperitoneum. Patients with mixed histologies tended to have worse International Germ Cell Cancer Collaborative Group risk compared to those with EC at orchiectomy (P =.037). Histology at PC-RPLND revealed fibrosis or necrosis in 76{\%}, mature teratoma in 19{\%} and viable cancer in 4{\%}. Over one-third of the patients had a residual mass of <1 cm prior to RPLND; of whom 15{\%} harbored mature teratoma in PC-RPLND histology. The Kaplan–Meier estimated probability of recurrence at 5 years of follow-up was 3.1{\%} (95{\%} CI 1.2{\%}, 8.0{\%}) for EC histology, 7.3{\%} lower than mixed histology. For cancer-specific mortality, the Kaplan–Meier estimated probability at 5 years was 4.6{\%} (95{\%} CI 3.3{\%}, 6.3{\%}) and 1.7{\%} (95{\%} CI 0.4{\%}, 6.8{\%}) for mixed and pure EC histologies, respectively. Conclusion: Approximately 20{\%} of patients with pure EC had teratoma at PC-RPLND. We have shown that those with a maximum node size of <1 cm should not be precluded from RPLND.",
author = "Dowling, {Catherine M.} and Melissa Assel and Musser, {John E.} and Meeks, {Joshua J.} and Sjoberg, {Daniel D.} and George Bosl and Robert Motzer and Dean Bajorin and Darren Feldman and Carver, {Brett S.} and Joel Sheinfeld",
year = "2018",
month = "4",
doi = "10.1016/j.urology.2018.01.014",
language = "English (US)",
volume = "114",
pages = "133--138",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

Dowling, CM, Assel, M, Musser, JE, Meeks, JJ, Sjoberg, DD, Bosl, G, Motzer, R, Bajorin, D, Feldman, D, Carver, BS & Sheinfeld, J 2018, 'Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen', Urology, vol. 114, pp. 133-138. https://doi.org/10.1016/j.urology.2018.01.014

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. / Dowling, Catherine M.; Assel, Melissa; Musser, John E.; Meeks, Joshua J.; Sjoberg, Daniel D.; Bosl, George; Motzer, Robert; Bajorin, Dean; Feldman, Darren; Carver, Brett S.; Sheinfeld, Joel.

In: Urology, Vol. 114, 04.2018, p. 133-138.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen

AU - Dowling, Catherine M.

AU - Assel, Melissa

AU - Musser, John E.

AU - Meeks, Joshua J.

AU - Sjoberg, Daniel D.

AU - Bosl, George

AU - Motzer, Robert

AU - Bajorin, Dean

AU - Feldman, Darren

AU - Carver, Brett S.

AU - Sheinfeld, Joel

PY - 2018/4

Y1 - 2018/4

N2 - Objective: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Methods: We compared those patients with 100% EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND. Results: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Twenty-six percent of patients presented with metastatic disease outside the retroperitoneum. Patients with mixed histologies tended to have worse International Germ Cell Cancer Collaborative Group risk compared to those with EC at orchiectomy (P =.037). Histology at PC-RPLND revealed fibrosis or necrosis in 76%, mature teratoma in 19% and viable cancer in 4%. Over one-third of the patients had a residual mass of <1 cm prior to RPLND; of whom 15% harbored mature teratoma in PC-RPLND histology. The Kaplan–Meier estimated probability of recurrence at 5 years of follow-up was 3.1% (95% CI 1.2%, 8.0%) for EC histology, 7.3% lower than mixed histology. For cancer-specific mortality, the Kaplan–Meier estimated probability at 5 years was 4.6% (95% CI 3.3%, 6.3%) and 1.7% (95% CI 0.4%, 6.8%) for mixed and pure EC histologies, respectively. Conclusion: Approximately 20% of patients with pure EC had teratoma at PC-RPLND. We have shown that those with a maximum node size of <1 cm should not be precluded from RPLND.

AB - Objective: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Methods: We compared those patients with 100% EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND. Results: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Twenty-six percent of patients presented with metastatic disease outside the retroperitoneum. Patients with mixed histologies tended to have worse International Germ Cell Cancer Collaborative Group risk compared to those with EC at orchiectomy (P =.037). Histology at PC-RPLND revealed fibrosis or necrosis in 76%, mature teratoma in 19% and viable cancer in 4%. Over one-third of the patients had a residual mass of <1 cm prior to RPLND; of whom 15% harbored mature teratoma in PC-RPLND histology. The Kaplan–Meier estimated probability of recurrence at 5 years of follow-up was 3.1% (95% CI 1.2%, 8.0%) for EC histology, 7.3% lower than mixed histology. For cancer-specific mortality, the Kaplan–Meier estimated probability at 5 years was 4.6% (95% CI 3.3%, 6.3%) and 1.7% (95% CI 0.4%, 6.8%) for mixed and pure EC histologies, respectively. Conclusion: Approximately 20% of patients with pure EC had teratoma at PC-RPLND. We have shown that those with a maximum node size of <1 cm should not be precluded from RPLND.

UR - http://www.scopus.com/inward/record.url?scp=85042210197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042210197&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2018.01.014

DO - 10.1016/j.urology.2018.01.014

M3 - Article

C2 - 29410311

AN - SCOPUS:85042210197

VL - 114

SP - 133

EP - 138

JO - Urology

JF - Urology

SN - 0090-4295

ER -